Study of recombinant human IFN-α-2b bacilli calmette-guerin activated killer cells and against bladder cancer cell in vitro
Authors:
- 1 October 2007
- journal article
- Published by Springer Nature in Frontiers of Medicine in China
- Vol. 1 (4) , 377-380
Abstract
Presently, one of the most potent immunotherapies is the application of bacillus Calmette Guerin (BCG) to prevent recurrences of the superficial bladder cancer. Despite its successful use, nonresponders and certain side effects remain a major obstacle. Therefore, current studies aim at developing recombinant BCG (rBCG) strains secreting Th1-like cytokines to improve the effectiveness of the therapy. In this study, a new type of rBCG strain constructed by Tianjin institute of Urology was tested for its immunostimulatory capacity in vitro. Peripheral blood monocytes (PBMC) were stimulated by recombinant BCG and transformed into bacilli Calmette-Guerin activated killer (BAK) cells, and the effect of anticancer BAK cells was studied. Recombinant IFN-α-2b-BCG, wild-type BCG (wBCG), wild-type BCG and IFN-α-2b were coincubated with PBMCs respectively in vitro, and the proliferation of PBMC was detected with MTT in different time. BAK cells have the ability to kill bladder tumor cells, and the antitumor activity of effecter cells was determined by LDH release assay. The result of MTT showed that the proliferation of PBMC in the recombinant BCG group was more powerful than in the other two groups (P < 0.05). The result of LDH release assay showed that the antitumor activity of BAK cells stimulated by Recombinant BCG was the highest in all groups. We conclude that the recombinant BCG can activate more PBMCs to anti-bladder cancer in vitro than wild-type BCG does.Keywords
This publication has 20 references indexed in Scilit:
- Bacillus calmete-guérin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicityUrologic Oncology: Seminars and Original Investigations, 2003
- Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasisBlood, 2001
- T Helper Cell Type 1–associated and Cytotoxic T Lymphocyte–mediated Tumor Immunity Is Impaired in Interleukin 4–deficient MiceJournal of Experimental Medicine, 1999
- Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent miceProceedings of the National Academy of Sciences, 1998
- Bacillus calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancerUrology, 1996
- Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette—Guérin (BCG) immunotherapyClinical and Experimental Immunology, 1995
- Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells.Journal of Experimental Medicine, 1993
- Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancerCancer Immunology, Immunotherapy, 1992
- Interferon-α Suppresses the Capacity of T Cells to Help Antibody Production by Human B CellsJournal of Interferon Research, 1992
- Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical Bacillus Calmette-GuerinUrological Research, 1989